Granted Patent
B2
US 12,600,763 · App. 17/883,427 · Granted Apr 14, 2026
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
Inventors:
Paul Brown (Boston, MA); Tyler L Carter (Newburyport, MA); Lyndon Fitzgerald Charles, Jr. (Medford, MA); Chase Spenser Coffman (Newton, MA); Daniel Benjamin Dadon (East Boston, MA); Lisa Liu (Somerville, MA); Sadiqua Shadbar (Allston, MA); Chaitanya Sudrik (Stoneham, MA); Yi Tang (Medford, MA); Shankul Vartak (Cambridge, MA)
Assignee:
Halozyme Hypercon, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.
Claims (18)
1 . A pharmaceutically effective composition comprising particles suspended in a carrier comprising fatty acid esters, wherein a plurality of the particles comprise at least one antibody or a fragment thereof, wherein the total weight percent of the at least one antibody or the fragment thereof in the plurality of particles is greater than 65%, and wherein the composition further comprises a hyaluronan degrading agent.
2 . The composition of claim 1 , wherein the carrier comprises fatty acid ethyl esters.
3 . The composition of claim 1 , wherein the carrier comprises ethyl oleate.
4 . The composition of claim 1 , wherein the particles have less than 10% aggregation of the at least one antibody or the fragment thereof.
5 . The composition of claim 1 , wherein the particles have less than 5% aggregation of the at least one antibody or the fragment thereof.
6 . The composition of claim 1 , wherein the particles have less than 3% aggregation of the at least one antibody or the fragment thereof.
7 . The composition of claim 1 , wherein the particles have a circularity from 0.80 to 1.00.
8 . The composition of claim 1 , wherein the particles have less than 3% residual moisture by weight.
9 . The composition of claim 1 , wherein the particles have greater than 70% of the at least one antibody or the fragment thereof by weight.
10 . The composition of claim 1 , wherein the particles have greater than 80% of the at least one antibody or the fragment thereof by weight.
11 . The composition of claim 1 , wherein the particles have less than 3% change in charge variants of the at least one antibody or the fragment thereof.
12 . The composition of claim 1 , wherein the particles further comprise at least one excipient selected from a carbohydrate, a pH adjusting agent, a salt, a chelator, a mineral, a polymer, a surfactant, a protein stabilizer, an emulsifier, an antiseptic, an amino acid, an antioxidant, a protein, an organic solvent, a paraben, a bactericide, a fungicide, a vitamin, a preservative, a nutrient media, analgesic, or a combination thereof.
13 . The composition of claim 1 , wherein the concentration of the at least one antibody or the fragment thereof in the composition is from 300 mg/mL to 650 mg/mL.
14 . The composition of claim 1 , wherein the concentration of the at least one antibody or the fragment thereof in the composition is from 400 mg/mL to 650 mg/mL.
15 . The composition of claim 1 , wherein the composition has a viscosity of less than 100 mPa·s.
16 . A pharmaceutically effective composition comprising particles suspended in a carrier comprising ethyl oleate, wherein a plurality of the particles comprise at least one antibody or fragment thereof, and have diameters in the range of 10 μm to 50 μm, wherein the total weight percent of the at least one antibody or fragment thereof in the plurality of particles is greater than 65%, wherein the concentration of the at least one antibody or the fragment thereof in the composition is from 300 mg/mL to 650 mg/mL, and wherein the composition further comprises a hyaluronan degrading agent.
17 . The composition of claim 1 , wherein the carrier comprises propylene glycol diesters.
18 . The composition of claim 1 , wherein the hyaluronan degrading agent is a hyaluronidase.
Assignments (2)
CHANGE OF NAME
Recorded Feb 2, 2026
From: ELEKTROFI, INC.
To: HALOZYME HYPERCON, INC.
Reel/Frame 073662/0717 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 26, 2022
From: BROWN, PAUL; CARTER, TYLER L.; CHARLES, LYNDON FITZGERALD, JR.; COFFMAN, CHASE SPENSER; DADON, DANIEL BENJAMIN; LIU, LISA; SHADBAR, SADIQUA; SUDRIK, CHAITANYA; TANG, YI; VARTAK, SHANKUL
To: ELEKTROFI, INC.
Reel/Frame 060910/0245 →
Continuity (6)
Continuation
PCTUS2020050508
· Sep 11, 2020
Provisional Application
63024703
· May 14, 2020
Provisional Application
62899907
· Sep 13, 2019
Provisional Application
62899981
· Sep 13, 2019
References Cited (275)
US 3013007A
· Dale et al.
· 1961
[cited by applicant]
US 3882036A
· Krezanoski et al.
· 1975
[cited by applicant]
US 4172896A
· Uno et al.
· 1979
[cited by applicant]
US 4531056A
· Abowsky et al.
· 1985
[cited by applicant]
US 5358970A
· Ruff et al.
· 1994
[cited by applicant]
US 5427798A
· Ludwig et al.
· 1995
[cited by applicant]
US 5541231A
· Ruff et al.
· 1996
[cited by applicant]
US 5595721A
· Kaminski et al.
· 1997
[cited by applicant]
US 5612055A
· Bedford et al.
· 1997
[cited by applicant]
US 5677180A
· Robinson et al.
· 1997
[cited by applicant]
US 5731000A
· Ruff et al.
· 1998
[cited by applicant]
US 5736137A
· Anderson et al.
· 1998
[cited by applicant]
US 5739169A
· Ocain et al.
· 1998
[cited by applicant]
US 5763493A
· Ruff et al.
· 1998
[cited by applicant]
US 5801005A
· Cheever et al.
· 1998
[cited by applicant]
US 5824311A
· Greene et al.
· 1998
[cited by applicant]
US 5830880A
· Sedlacek et al.
· 1998
[cited by applicant]
US 5840731A
· Mayer et al.
· 1998
[cited by applicant]
US 5846945A
· Mccormick
· 1998
[cited by applicant]
US 5874029A
· Subramaniam et al.
· 1999
[cited by applicant]
US 6095134A
· Sievers et al.
· 2000
[cited by applicant]
US 6110973A
· Young
· 2000
[cited by applicant]
US 7001888B2
· Tidmarsh et al.
· 2006
[cited by applicant]
US 8013022B2
· Deangelo et al.
· 2011
[cited by applicant]
US 8512754B2
· Needham
· 2013
[cited by applicant]
US 8728525B2
· Brown et al.
· 2014
[cited by applicant]
US 8939388B1
· Beetz et al.
· 2015
[cited by applicant]
US 9259701B2
· Palmer et al.
· 2016
[cited by applicant]
US 9364542B2
· Chang
· 2016
[cited by applicant]
US 9597385B2
· Caplan
· 2017
[cited by applicant]
US 9643996B2
· Petrel et al.
· 2017
[cited by applicant]
US 20010031801A1
· Lyons et al.
· 2001
[cited by applicant]
US 20020081732A1
· Bowlin et al.
· 2002
[cited by applicant]
US 20030055010A1
· De Haan
· 2003
[cited by applicant]
US 20050019410A1
· Johnson
· 2005
[cited by applicant]
US 20050186183A1
· Deangelo et al.
· 2005
[cited by applicant]
US 20060002862A1
· Truong-Le et al.
· 2006
[cited by applicant]
US 20060147400A1
· Piot
· 2006
[cited by applicant]
US 20060292224A1
· Moore et al.
· 2006
[cited by applicant]
US 20080026068A1
· Brown et al.
· 2008
[cited by applicant]
US 20080095849A1
· Wu et al.
· 2008
[cited by applicant]
US 20090035381A1
· Stankus et al.
· 2009
[cited by applicant]
US 20100092526A1
· Baker et al.
· 2010
[cited by applicant]
US 20100305500A1
· Lambert et al.
· 2010
[cited by applicant]
US 20100330169A1
· Bunick et al.
· 2010
[cited by applicant]
US 20110223208A1
· Hill et al.
· 2011
[cited by applicant]
US 20120244196A1
· Okubo et al.
· 2012
[cited by applicant]
US 20120258914A1
· Kumar et al.
· 2012
[cited by applicant]
US 20140052020A1
· Allen et al.
· 2014
[cited by applicant]
US 20140262694A1
· Knigge
· 2014
[cited by applicant]
US 20140308270A1
· Lobo et al.
· 2014
[cited by applicant]
US 20140348852A1
· Vos et al.
· 2014
[cited by applicant]
US 20140378370A1
· Johnston et al.
· 2014
[cited by applicant]
US 20160128944A1
· Chawrai et al.
· 2016
[cited by applicant]
US 20160250329A1
· Bukrinski et al.
· 2016
[cited by applicant]
US 20170210554A1
· Black et al.
· 2017
[cited by applicant]
US 20220211627A1
· Arrighi et al.
· 2022
[cited by applicant]
US 20230065628A1
· Auer et al.
· 2023
[cited by applicant]
US 20230094393A1
· Charles et al.
· 2023
[cited by applicant]
US 20230338299A1
· Paul et al.
· 2023
[cited by applicant]
US 20240255517A1
· Carter et al.
· 2024
[cited by applicant]
US 20240270864A1
· Brown et al.
· 2024
[cited by applicant]
US 20250025425A1
· Brown et al.
· 2025
[cited by applicant]
US 20250026811A1
· Brown et al.
· 2025
[cited by applicant]
US 20250082736A1
· Brown et al.
· 2025
[cited by applicant]
US 20250186348A1
· Coffman et al.
· 2025
[cited by applicant]
US 20250288525A1
· Auer et al.
· 2025
[cited by applicant]
CN 1750811A
· 2006
[cited by applicant]
CN 103908432A
· 2014
[cited by applicant]
EP 0677332A2
· 1995
[cited by applicant]
EP 3236987B1
· 2020
[cited by applicant]
EP 2773330B1
· 2020
[cited by applicant]
JP 2003513710A
· 2003
[cited by applicant]
JP 2005504090A
· 2005
[cited by applicant]
JP 2005504764A
· 2005
[cited by applicant]
JP 2008266128A
· 2008
[cited by applicant]
JP 2010524948A
· 2010
[cited by applicant]
JP 2011079747A
· 2011
[cited by applicant]
JP 2011241223A
· 2011
[cited by applicant]
JP 2012500799A
· 2012
[cited by applicant]
JP 2012508744A
· 2012
[cited by applicant]
JP 2013166100A
· 2013
[cited by applicant]
JP 2014058466A
· 2014
[cited by applicant]
JP 2014510077A
· 2014
[cited by applicant]
JP 2014129357A
· 2014
[cited by applicant]
JP 2019535832A
· 2019
[cited by applicant]
WO 9911196A1
· 1999
[cited by applicant]
WO 0335301A1
· 2003
[cited by applicant]
WO 2006087354A2
· 2006
[cited by applicant]
WO 2007059782A1
· 2007
[cited by applicant]
WO 2008062908A1
· 2008
[cited by applicant]
WO 2008092084A2
· 2008
[cited by applicant]
WO 2010044867A1
· 2010
[cited by applicant]
WO 2010082543A1
· 2010
[cited by applicant]
WO 2011131943A2
· 2011
[cited by applicant]
WO 2012042274A1
· 2012
[cited by applicant]
WO 2014057424A2
· 2014
[cited by applicant]
WO 2015085898A1
· 2015
[cited by applicant]
WO 2015138844A1
· 2015
[cited by applicant]
WO 2015196091A1
· 2015
[cited by applicant]
WO 2016014497A1
· 2016
[cited by applicant]
WO 2016089309A1
· 2016
[cited by applicant]
WO 2017106716A1
· 2017
[cited by applicant]
WO 2018098376A1
· 2018
[cited by applicant]
WO 2018234489A1
· 2018
[cited by applicant]
WO 2019023392A1
· 2019
[cited by applicant]
WO 2019226969A1
· 2019
[cited by applicant]
WO 2020051307A1
· 2020
[cited by applicant]
WO 2020160323A2
· 2020
[cited by applicant]
WO 2021050953A1
· 2021
[cited by applicant]
WO 2021158959A2
· 2021
[cited by applicant]
WO 2021168271A1
· 2021
[cited by applicant]
WO 2021212019A1
· 2021
[cited by applicant]
WO 2022256840A2
· 2022
[cited by applicant]
WO 2023212721A1
· 2023
[cited by applicant]
WO 2024177927A1
· 2024
[cited by applicant]
WO 2025054552A1
· 2025
[cited by applicant]
Capelle, M.A.H. et al., “High throughout screening of protein formulation stability: Practical considerations,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 65; 131-148 (2007).
[cited by applicant]
Clackson, T. et al., “Making antibody fragments using phage display libraries,” Nature vol. 352; 624-628 (1991).
[cited by applicant]
CN Search report Mailed on Jan. 13, 2024 for CN Application No. 2021800293477 (with English Translation).
[cited by applicant]
CN Search report Mailed on Jul. 28, 2022 for CN Application No. 202080012222.9 (With English Translation).
[cited by applicant]
English Translation of CN Office Action Mailed on Aug. 3, 2022 for CN Application No. 202080012222.9.
[cited by applicant]
English translation of Office Action issued in Chinese Patent Application No. 201780072350.0, issued May 17, 2021 (16 pages).
[cited by applicant]
Hui et al., “Progress in preparation of peptide protein drug microspheres,” The medicine herald, Issue 10, 2007, pp. 1-32. (Concise explanation met by English Translation of Search report cited concurrently as Other Doc…
[cited by applicant]
Jones, A.J.S., “Analysis of Polypeptides and Proteins,” Advanced Drug Delivery Reviews, vol. 10; 29-90 (1993).
[cited by applicant]
Marks, J.D. et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J. Mol. Biol., vol. 222; 581-597 (1991).
[cited by applicant]
Persic, L. et al., “An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries,” Gene; 9-18 (1997).
[cited by applicant]
Press, O.W. et al., “Monoclonal Antibody 1F5 (Anti-CD20) Serotherapy of Human B Cell Lymphoma,” Blood, vol. 69; No. 2; 584-591 (1987).
[cited by applicant]
Reichardt, C., “Solvatochromic Dyes as Solvent Polarity Indicators,” Chem. Rev., vol. 94; 2319-2358 (1994).
[cited by applicant]
Richardson, H. et al., “Influence of the glass transition on solvent loss from spin-cast glassy polymer thin films,” Eur. Phys. J. E, vol. 12; 021; S87-S91 (2003).
[cited by applicant]
Sblattero, D. and Bradbury, A., “Exploiting recombination in single bacteria to make large phage antibody libraries,” Nature Biotechnology, vol. 18; 75-80 (2000).
[cited by applicant]
Supplementary Partial European Search Report for European Patent Application No. 17873547.8, dated Jun. 15, 2020 (9 pages).
[cited by applicant]
Zhiqi, L., et al., “Functional Emulsifiers and Emulsions”, China Light Industry Press, Apr. 30, 2000, 2 pages. (Concise explanation met by Translation of Search report being cited as Other Document 3 in IDS being cited …
[cited by applicant]
Notice of Allowance for U.S. Appl. No. 17/351,963, mailed May 4, 2022.
[cited by applicant]
Bock et al.,“Electrospraying of polymers with therapeutic molecules: state of the art,” Prag Polym Sci. 37(11): 1510-1551 (2012)(67 pages).
[cited by applicant]
Cloupeau et al., “Electrohydrodynamic spraying functioning modes: a critical review,” J Aerosol Sci. 25(6): 1021-1036 (1994).
[cited by applicant]
Elektrofi, Inc., Redefining the Delivery of Biologics, 11 pages, retrieved from Internet URL: https://www.elektrofi.com/welcome#technology on Nov. 15, 2021.
[cited by applicant]
European Search Report and Search Opinion Received for EP Application No. 18838118, mailed on May 6, 2021, 12 pages.
[cited by applicant]
Forgacs, E. et al., “Direct (Normal)-Phase High-Performance Liquid Chromatography,” Chapter II.B. in Molecular Basis of Chromatographic Separation, CRC Press, Baco Raton, FL; 120-131 (1997).
[cited by applicant]
Galam et al., “High-throughput assay for the identification ofHsp90 inhibitors based on Hsp90dependent refolding of firefly luciferase,” available in PMC Mar. 1, 2008, published in final edited form as: Bioorg Med Chem.…
[cited by applicant]
Ganan-Calvo et al., “Current and droplet size in the electrospraying ofliquids. Scaling laws,” J Aerosol Sci. 28(2): 249-275 (1997).
[cited by applicant]
Gapinski et al., “Structure and dimensions of core-shell nanoparticles comparable to the confocal volume studied by means of fluorescence correlation spectroscopy,” Langmuir. 32(10): 2482-2491 (2016).
[cited by applicant]
Gikanga et al.,“ Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying-the Road to Manufacturing Scale,” PDA J Pharm Sci Technol. 69(1): 59-73 (2015) (16 pages).
[cited by applicant]
Giugliano et al., “Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a ra…
[cited by applicant]
Haggag et al., “Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins,” Front Pharmacol. 6:140 (2015) (5 pages).
[cited by applicant]
Hickey, J.W. et al., “Biologically Inspired Design ofNanoparticle Artificial Antigen-Presenting Cells for Immunomodulation,” Nano Letters, vol. 17; 7045-7054 )2017).
[cited by applicant]
Xie et al., “Encapsulation of protein drugs in biodegradable microparticles by co-axial electrospray,” J Colloid Interface Sci. 317(2): 469-76 (2008).
[cited by applicant]
Wanning et al., “Pharmaceutical spray freeze drying,” Int J Pharm. 488(1-2): 136-53 (2015).
[cited by applicant]
Wang et al., “FDA's regulatory science program for generic PLAI PLGA-based drug products,” Am Phann Rev. <https://www.americanpharmaceuticalrevie,v.com/Featured-Articles/ 188841-FDA-s-Regulatory-Science-Program-for-Gene…
[cited by applicant]
Vonhoff, Sebastian, Thesis: “The Influence of Atomization Conditions on Protein Secondary and Tertiary Structure During Microparticle Formation by Spray-Freezing-Drying,” Doktorgrades Dr. rer. nat, Der Natunvissenschaft…
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2020/050508, mailed on Dec. 3, 2020, 12 pages.
[cited by applicant]
Vehring, “Pharmaceutical particle engineering via spray drying,” Pharm Res. 25(5): 999-1022 (2008).
[cited by applicant]
Torchilin. “Multifunctional nanocarriers,” Adv Drua Deliv Rev. 58(14): 1532-55 (2006).
[cited by applicant]
Takats et al., “Electrosonic spray ionization. A gentle technique for generating folded proteins and protein complexes in the gas phase and for studying ion-molecule reactions at atmospheric pressure,” Anal Chem. 76(14)…
[cited by applicant]
Janssen Biotech Inc., “Highlights of prescribing information,” <http://www.janssenlabels.com/package-insert/product-monograph/prescribinginformation/DARZALEX-pi.pdl>, dated Jul. 2019, retrieved on Aug. 22, 2019 (13 page…
[cited by applicant]
Kaltashov et al., “Electrospray ionization mass spectrometry can provide estimates of protein surface areas in solution,” available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 (…
[cited by applicant]
Kim et al., “Controlled production of emulsion drops using an electric field in a flow-focusing microfluidic device,” Appl Phys Lett. 91: 133106 (2007) (3 Pages).
[cited by applicant]
Ku et al., “Electrospray characteristics of highly viscous liquids,” J Aerosol Sci. 33(10): 1361-1378 (2002).
[cited by applicant]
Lal et al., “Clean western blot signals from immunoprecipitated samples,” available in PMC Jan. 25, 2006, published in final edited form as: Mol Cell Probes. 19(6): 385-388 (2005) (5 pages).
[cited by applicant]
Lavorini et al., “New inhaler devices—the good, the bad and the ugly,” Respiration. 88(1): 3-15 (2014).
[cited by applicant]
Lee et al., “Solid-state stabilization of a-Chymotrypsin and catalase with carbohydrates,” Ind Eng Chem Res. 45(14): 5134-5147 (2006).
[cited by applicant]
Li et al., “Effects of pulsed electric fields and heat treatment on stability and secondary structure of bovine immunoglobulin G,” J Agric Food Chem. 53(3): 663-670 (2005).
[cited by applicant]
Longman et al.,“ Identifying differences in solution Conformations ofhvo chimeric IgG3 antibodies through triple detection SEC,” LCGC North America. 18(21): (2006) (5 pages).
[cited by applicant]
Lopez-Herrera et al., “Coaxial jets generated from electrified Taylor cones. Scaling laws,” J Aerosol Sci. 34(5): 535-552 (2003).
[cited by applicant]
Miller et al., “Antibody nanoparticle dispersions formed with mixtures of crowding molecules retain activity and in vivo bioavailability,” available in PMC Oct. 1, 2013, published in final edited form as: J Pharm Sci. 1…
[cited by applicant]
Miller et al., “Low viscosity highly concentrated injectable nonaqueous suspensions of lysozyme microparticles,” available in PMC Feb. 17, 2011, published in final edited form as: Langmuir. 26(2): 1067-1074 (2010) (22 p…
[cited by applicant]
Moghadam et al., “Electro-spray of high viscous liquids for producing mono-sized spherical alginate beads,” Particuology. 6(4): 271-275 (2008).
[cited by applicant]
Morales-Cruz et al., “Two-step nanoprecipitation for the production of protein-loaded PLGA nanospheres,” Results Pharma Sci. 2: 79-85 (2012).
[cited by applicant]
Mueller et al.,“The rheology of suspensions of solid particles,” Proc R Soc A. 466: 1201-1228 (2010).
[cited by applicant]
Naqvi et al., “Living cell factories—electrosprayed microcapsules and microcarriers for minimally invasive delivery,” Adv Mater. 28(27): 5662-71 (2016)(10 pages).
[cited by applicant]
Nguyen et al., “Pharmaceutical applications of electrospraying,” J Pharm Sci. 105(9): 2601-2620 (2016).
[cited by applicant]
Park et al., “One step immobilization of protein encapsulated core/shell particles onto nanofibers,” Macromol Mater Eng. 295(6): 544-550 (2010).
[cited by applicant]
Patel et al. “Poloxamers: A pharmaceutical excipients with therapeutic behaviors”, 2009, 15, International Journal of PharmTech Research, vol. (1), No. 2, pp. 299-303.
[cited by applicant]
Pivnik, A.V., “Use of rituximab for treatment of HIV-infected patients with hematological disorders, ” Genotekhnologiya Medical Center, Moscow, 7 pages; English Abstract Only (2013).
[cited by applicant]
Saglam et al., “Preparation of high protein micro-particles using two-step emulsification,” Food Hydrocolloids. 25(5):1139-48 (2011).
[cited by applicant]
Serra-Peinado, C., et al., “Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab,” Nature Communications, vol. 10; 15 pages (2019).
[cited by applicant]
Shire et al., “Challenges in the development of high protein concentration formulations,” J Pharm Sci. 93(6): 1390-402 (2004).
[cited by applicant]
Allahham, D. et al., “Development and application of a micro-capillary rheometer for in-vitro evaluation of parenteral Injectability,” Journal of Pharmacy and Pharmacology, vol. 56; 709-716 (2004).
[cited by applicant]
Aniket et al., “MicroglassificationTM: A novel technique for protein dehydration,” J Pharm Sci. 103(3): 810-820 (2014).
[cited by applicant]
Banerjee et al., “Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte,” Int J Anal Chem. Article 282574 (2012) (40 pages).
[cited by applicant]
Bogelein et al., “Cyclone selection influences protein damage during drying in a mini spray-dryer,” Int J Pharm. 401 (1-2): 68-71 (2010).
[cited by applicant]
Cloupeau et al., “Electrostatic spraying of liquids: Main functioning modes,” J Electrostat. 25(2): 165-184 (1990).
[cited by applicant]
Dias et al., “Tolerability of High-vol. Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects,” AAPS PharmSciTech. 16(5): 1101-1107 (2015).
[cited by applicant]
Fernandez de la Mora et al., “The current emitted by highly conducting taylor cones,” J Fluid Mech. 260: 155-184 (1994).
[cited by applicant]
Yuan et al., “Coaxial electrospray of curcumin-loaded microparticles for sustained drug release,” PLoS One. 10(7): e0132609 (2015) (15 pages).
[cited by applicant]
Yuan et al., “One-step fabrication of triple-layered microcapsules by a tri-axial flow focusing device for microencapsulation of soluble drugs and imaging agents,” Proc SPIE vol. 9711, Imaging, Manipulation, and Analysi…
[cited by applicant]
Fernandez de la Mora et al., “The fluid dynamics of Taylor cones,” Annu Rev Fluid Mech. 39: 217-43 (2007) (29 pages).
[cited by applicant]
Informa Healthcare, Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, vol. 3: Regulations, Validation and the Future. Sandeep Nema and John D. Ludwig, vii-304 (2010) (328 pages).
[cited by applicant]
Lee, Spray-Drying of Proteins. Rational Design of Stable Protein Formulations. Carpenter and Manning, 135-158 (2002).
[cited by applicant]
Loscertales et al., “Micro/nano encapsulation via electrified coaxial liquid jets,” Science. 295(5560): 1695-8 (2002).
[cited by applicant]
Makadia et al., “Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier,” Polymers (Basel). 3(3): 1377-1397 (2011).
[cited by applicant]
U.S. Department of Health and Human Services, “Q3C—Tables and List: Guidance for Industry,” Aug. 2018 (10 pages).
[cited by applicant]
Zhang et al., “Coaxial electrospray of microparticles and nanoparticles for biomedical applications,” Expert Rev Med Devices. 9(6): 595-612 (2012).
[cited by applicant]
Zhang et al., “Coaxial electrospray of ranibizumab-loaded microparticles for sustained release of anti-VEGF therapies,” PloS One. 10(8):e0135608 (2015) (16 pages).
[cited by applicant]
Ziabicki et al., “Crystal nucleation in an electric field,” Macromol Symp. 104(1): 65-87 (1996).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/351,963, mailed Oct. 21, 2021.
[cited by applicant]
Final Office Action for U.S. Appl. No. 17/351,963, mailed Feb. 1, 2022.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/050508, entitled: “Compositions and Methods for the Delivery of Therapeutic Biologics for Treatment of Disease,” mailed Mar.…
[cited by applicant]
Fenn et al., “Electrospray ionization for mass spectrometry of large biomolecules,” Science. 246(4926):64-71 (Oct. 6, 1989).
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/906,489, mailed Feb. 14, 2025.
[cited by applicant]
Frost, G.I., “Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration,” Expert Opinion Drug Deliv., vol. 4; No. 4; 427-440 (2007).
[cited by applicant]
Gulfam, M. et al., “Anticancer Drug-Loaded Gliadin Nanoparticles Induce Apoptosis in Breast Cancer Cells,” American Chemical Society, Langmuir, vol. 28; 8216-8223 (2012).
[cited by applicant]
Hui et al., “Progress in preparation of peptide protein drug microspheres,” The medicine herald, Issue 10, 2007, pp. 1-32. (Concise explanation met by English Translation of Search report attached).
[cited by applicant]
Imamura, K et al., “Evaluation of Hydration States of Protein in Freeze-Dried Amorphous Sugar Matrix,” J. Pharm. Sci., vol. 90; 1955-1963 (2001).
[cited by applicant]
Imamura, K., “Sugar-Protein Interaction and Stabilization of Protein in Amorphous Sugar Matrix,” Cryobiology and Cryotechnology, vol. 51; No. 1; 31-35 (2005). English Abstract included.
[cited by applicant]
Jun, L., “Guizho Science and Technology Press”, Agricultural building materials, Aug. 31, 1999, 4 pages (Concise explanation met by the attached English Translation of CN Appl 202080064558 office action).
[cited by applicant]
Kaltashov et al., “Estimates of Protein Surface Areas in Solution by Electrospray Ionization Mass Spectrometry,” available in PMC Jan. 27, 2009, published in final edited form as: Anal Chem. 77(16): 5370-5379 (2005).
[cited by applicant]
Mardles. E. W. J., “Viscosity of Suspensions and the Einstein Equation,” Nature. 145: 970 (Jun. 22, 1940).
[cited by applicant]
Miller et al. (Low viscosity highly concentrated injectable non-aqueous suspension of lysosome microparticles, Languir, Jan. 19, 2010; 26 (2): 1067-1074). (Year: 2010).
[cited by applicant]
Nema et al., Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, vol. 3: Requlations, Validation and the Future. Informa Healthcare, vii-304 (2010) (328 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/906,489, mailed Nov. 29, 2024.
[cited by applicant]
Papir, Y.S. and Krieger, I.M., “Rheological Studies on Dispersions of Uniform Colloidal Spheres,” Journal of Colloid and Interface Science, vol. 34; No. 1; 126-130 (1970).
[cited by applicant]
Pearlman, R. and Nguyen, T.H., “Analysis of Protein Drugs,” Peptide and Protein Drug Delivery, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, pp. 247-301 (1991).
[cited by applicant]
Plückthun, A., “Antibodies from
[cited by applicant]
Sridhar, R. and Ramakrishna, S., “Electrosprayed nanoparticles for drug delivery and pharmaceutical applications,” Biomatter, vol. 3; No. 3; e24281-1; 14 pages (2013).
[cited by applicant]
Vehring, R. et al., “Particle formation in spray drying,” Aerosol Science, vol. 38; 728-746 (2007).
[cited by applicant]
Zhang, J. et al., “Fundamentals and applications of inertial microfluidics: a review,” Lab Chip, vol. 16; 10-34 (2016).
[cited by applicant]
English language abstract for JP 2010609243 A5, 2011, 1 page. (Year: 2011).
[cited by applicant]
Nema et al., Pharmaceutical Dosage Forms: Parenteral Medications, Third Edition, vol. 3: Regulations, Validation and the Future. Informa Healthcare, vii-304 (2010) (328 pages).
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/906,489, mailed Jun. 5, 2025.
[cited by applicant]
Sah et al.; “Recent Trends in Preparation of Poly(lactide-co-glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent,” 2015; Hindawi Publishing Corporation; Journal of Nanomaterials, vol. 2015, Ar…
[cited by applicant]
English Translation of CN Office Action Mailed on Aug. 3, 2022 for CN Application No. 202080012222.9, 4 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/906,489, mailed Sep. 4, 2025.
[cited by applicant]
Gross-Rother et al., “Particle Detection and Characterization for Biopharmaceutical Applications: Current Principles of Established and Alternative Techniques”, Pharmaceutics, vol. 12, No. 11, Nov. 19, 2020, 49 pages.
[cited by applicant]
Jack et al., “Analysis of particulate contaminations of infusion solutions in a pediatric intensive care unit”, Intensive Care Medicine, vol. 36, No. 4, Feb. 18, 2010, pp. 707-711.
[cited by applicant]
Jones, A.J.S., “Analysis of Polypeptides and Proteins,” Advanced Drug Delivery Reviews, vol. 10; p. 29-90 (1993).
[cited by applicant]
Oxford Dictionary (2024, one page) (Year: 2024).
[cited by applicant]
Zhiqi, L., et al., “Functional Emulsifiers and Emulsions”, China Light Industry Press, Apr. 30, 2000, 2 pages. (Concise explanation met by English Translation of Search report attached).
[cited by applicant]